Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray.

To monitor severe acute respiratory syndrome (SARS) infection, a coronavirus protein microarray that harbors proteins from SARS coronavirus (SARS-CoV) and five additional coronaviruses was constructed. These microarrays were used to screen approximately 400 Canadian sera from the SARS outbreak, including samples from confirmed SARS-CoV cases, respiratory illness patients, and healthcare professionals. A computer algorithm that uses multiple classifiers to predict samples from SARS patients was developed and used to predict 206 sera from Chinese fever patients. The test assigned patients into two distinct groups: those with antibodies to SARS-CoV and those without. The microarray also identified patients with sera reactive against other coronavirus proteins. Our results correlated well with an indirect immunofluorescence test and demonstrated that viral infection can be monitored for many months after infection. We show that protein microarrays can serve as a rapid, sensitive, and simple tool for large-scale identification of viral-specific antibodies in sera.

[1]  S. Dudoit,et al.  Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .

[2]  P. Lim,et al.  Antibody Response of Patients with Severe Acute Respiratory Syndrome (SARS) Targets the Viral Nucleocapsid , 2004, The Journal of infectious diseases.

[3]  Ping Li,et al.  Diagnosis of Severe Acute Respiratory Syndrome (SARS) by Detection of SARS Coronavirus Nucleocapsid Antibodies in an Antigen-Capturing Enzyme-Linked Immunosorbent Assay , 2003, Journal of Clinical Microbiology.

[4]  M. R. Macnaughton,et al.  Antibody to virus components in volunteers experimentally infected with human coronavirus 229E group viruses , 1981, Infection and immunity.

[5]  Peter E. Hart,et al.  Nearest neighbor pattern classification , 1967, IEEE Trans. Inf. Theory.

[6]  Mia Hubert,et al.  Integrating robust clustering techniques in S-PLUS , 1997 .

[7]  M. Arnaud,et al.  Puces à protéines et perspectives d’applications médicales , 2007, IRBM.

[8]  C. Fraser,et al.  Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong , 2003, The Lancet.

[9]  Huanming Yang,et al.  Assessment of Immunoreactive Synthetic Peptides from the Structural Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2003, Clinical chemistry.

[10]  F. Nolte,et al.  Preclinical Evaluation of Two Real-Time, Reverse Transcription-PCR Assays for Detection of the Severe Acute Respiratory Syndrome Coronavirus , 2004, Journal of Clinical Microbiology.

[11]  H. E. Krause,et al.  Coronavirus Infection in Acute Lower Respiratory Tract Disease of Infants , 1974, The Journal of infectious diseases.

[12]  I Hinberg,et al.  Receiver operator characteristic (ROC) curves and non-normal data: an empirical study. , 1990, Statistics in medicine.

[13]  Y. Guan,et al.  Early diagnosis of SARS Coronavirus infection by real time RT-PCR , 2003, Journal of Clinical Virology.

[14]  Chin-Tarng Lin,et al.  Disease-specific B cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens , 2004, The Journal of infectious diseases.

[15]  Dieter Stoll,et al.  A microarray enzyme‐linked immunosorbent assay for autoimmune diagnostics , 2000, Electrophoresis.

[16]  S. Wildt,et al.  The humanization of N-glycosylation pathways in yeast , 2005, Nature Reviews Microbiology.

[17]  M. Gerstein,et al.  Analysis of yeast protein kinases using protein chips , 2000, Nature Genetics.

[18]  Y. Guan,et al.  Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.

[19]  K. Chan,et al.  Evaluation and Validation of an Enzyme-Linked Immunosorbent Assay and an Immunochromatographic Test for Serological Diagnosis of Severe Acute Respiratory Syndrome , 2004, Clinical Diagnostic Laboratory Immunology.

[20]  P. Woo,et al.  Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus , 2004, Clinical Diagnostic Laboratory Immunology.

[21]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[22]  V. ter meulen,et al.  Detection of human coronavirus 229E-specific antibodies using recombinant fusion proteins , 1995, Journal of Virological Methods.

[23]  P. Hsueh,et al.  Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS‐associated coronavirus , 2004, Clinical Microbiology and Infection.

[24]  S. Schreiber,et al.  Printing proteins as microarrays for high-throughput function determination. , 2000, Science.

[25]  H. Akaike.  A new look at the statistical model identification , 1974 .

[26]  L. Pagani,et al.  Prevalence of antibody to human coronaviruses 229E, OC43 and neonatal calf diarrhea coronavirus (NCDCV) in patients of Northern Italy , 1986, European Journal of Epidemiology.

[27]  J. Sung,et al.  Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study , 2003, BMJ : British Medical Journal.